89Zr-mAb3481 PET for HER3 tumor status assessment during lapatinib treatment.

about

Clinical Potential of Human Epidermal Growth Factor Receptor 2 and Human Epidermal Growth Factor Receptor 3 Imaging in Breast Cancer

P2860

Q57110662-4B661F3C-F1D5-49A9-8A8B-A7382E1B3840

P2860

89Zr-mAb3481 PET for HER3 tumor status assessment during lapatinib treatment.

Item

http://www.wikidata.org/entity/Q43992554

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

89Zr-mAb3481 PET for HER3 tumor status assessment during lapatinib treatment.

@en

89Zr-mAb3481 PET for HER3 tumor status assessment during lapatinib treatment.

@nl

type

Item

label

89Zr-mAb3481 PET for HER3 tumor status assessment during lapatinib treatment.

@en

89Zr-mAb3481 PET for HER3 tumor status assessment during lapatinib treatment.

@nl

prefLabel

89Zr-mAb3481 PET for HER3 tumor status assessment during lapatinib treatment.

@en

89Zr-mAb3481 PET for HER3 tumor status assessment during lapatinib treatment.

@nl

P1476

89Zr-mAb3481 PET for HER3 tumor status assessment during lapatinib treatment.

@en

P2093

Anton G T Terwisscha van Scheltinga

http://www.w3.org/2001/XMLSchema#string

Arjan Kol

http://www.w3.org/2001/XMLSchema#string

Marjolijn N Lub-de Hooge

http://www.w3.org/2001/XMLSchema#string

Martin Pool

http://www.w3.org/2001/XMLSchema#string

Steven de Jong

http://www.w3.org/2001/XMLSchema#string

P2860

A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor

The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation

A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding

Targeting of erbB3 receptor to overcome resistance in cancer treatment

Profiling the HER3/PI3K pathway in breast tumors using proximity-directed assays identifies correlations between protein complexes and phosphoproteins.

ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics.

Phase 1 Evaluation of [(64)Cu]DOTA-Patritumab to Assess Dosimetry, Apparent Receptor Occupancy, and Safety in Subjects with Advanced Solid Tumors.

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors.

89Zr immuno-PET: comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies.

ImmunoPET and biodistribution with human epidermal growth factor receptor 3 targeting antibody ⁸⁹Zr-RG7116

P304

1370-1378

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/19420862.2017.1371382

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Elisabeth de Vries

P577

2017-09-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28873009

http://www.w3.org/2001/XMLSchema#string

P932

5680796

http://www.w3.org/2001/XMLSchema#string

89Zr-mAb3481 PET for HER3 tumor status assessment during lapatinib treatment.

about

P2860

P2860

89Zr-mAb3481 PET for HER3 tumor status assessment during lapatinib treatment.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932